Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.

Camrelizumab will be administered 6 weeks post-tumor resection.

SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).

Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.